|
|
|
|
Alkermes Retains Neutral Rec
We maintain our Neutral rating on Alkermes, Inc.(ALKS) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system...
|
|
|
Alkermes Retains Neutral Rec
We maintain our Neutral rating on Alkermes, Inc.(ALKS - Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and...
|
|
|
Alkermes Retains Neutral Rec - Analyst Blog
We maintain our Neutral rating on Alkermes, Inc.( ALKS ) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous...
|
|
|
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
Record Sales of RISPERDAL CONSTA Company Expands Proprietary Pipeline to Include Long-Acting Versions of Two Blockbuster Medications WALTHAM, Mass.--(BUSINESS WIRE)--Feb 4, 2010 - Alkermes, Inc.(NASDAQ: ALKS) today reported financial results for its third...
|
|
|
Strong 3Q Sales for Alkermes
Alkermes' ALKS reported fiscal third-quarter results with sales coming in slightly above our expectations.We will maintain our fair value estimate, though, as this performance does not change our long-term outlook for the firm. Revenues rose to $44 million...
|
|
|
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
WALTHAM, Mass.-- (BUSINESS WIRE) -- Alkermes, Inc.(NASDAQ: ALKS) today reported financial results for its third quarter of fiscal 2010, which ended on December 31, 2009. Financial highlights: Quarterly revenues of $44.2 million, driven by record...
|
|
|
Alkermes, Inc. (ALKS) Third-Quarter Review
Analysts at Leerink Swann have released a report reviewing the third-quarter at Alkermes, Inc.(NASDAQ: ALKS ). The company reported results for the third-quarter yesterday. Alkermes, Inc. reported revenue of $44 million, which was above analysts...
|
|
|
Lower Q3 Loss for Alkermes - Analyst Blog
Alkermes Inc.( ALKS ) reported a third quarter fiscal 2010 net loss of 3 cents per share (excluding items but including stock based compensation) compared with a loss of 9 cents in the year-ago period (excluding the impact of the termination of the...
|
|
|
Analyst upgrades Alkermes on sales of Risperdal Consta, and expected diabetes drug ruling
NEW YORK Strong sales of a schizophrenia drug during the third quarter prompted an analysts to upgrade shares of Alkermes Inc.on Friday. Shares jumped 10 percent, or $1.10, to $11.62 in premarket trading. Jefferies and Co. analyst David Windley...
|
|
|
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
4:00 PM EST News source: Business Wire Alkermes, Inc.(NASDAQ: ALKS) today reported financial results for its third quarter of fiscal 2010, which ended on December 31, 2009. Financial highlights: Other recent highlights: The record RISPERDAL CONSTA sales in...
|
|
|
Alkermes reports 3Q loss, smaller than expected
CAMBRIDGE, Mass.-- Biotech drug developer Alkermes Inc. on Thursday reported a fiscal 2010 third-quarter loss on lower revenue, but the results topped Wall Street expectations. Alkermes said it lost $6.8 million, or 7 cents per share, in the quarter...
|
|
|
Alkermes reports fiscal 3rd-quarter loss on revenue dip, but smaller than expected
CAMBRIDGE, MASS.Biotech drug developer Alkermes Inc. on Thursday reported a fiscal 2010 third-quarter loss on lower revenue, but the results topped Wall Street expectations. Alkermes said it lost $6.8 million, or 7 cents per share, in the quarter ended...
|
|
|
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
- Record Sales of RISPERDAL CONSTA- - Company Expands Proprietary Pipeline to Include Long-Acting Versions of Two Blockbuster Medications - WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc.(NASDAQ: ALKS) today reported financial results for its third quarter...
|
|
|
Alkermes Inc. Reports Operating Results (10-Q)
Posted by: gurufocus (IP Logged) Alkermes Inc.(ALKS) filed Quarterly Report for the period ended 2009-12-31. Alkermes Inc. has a market cap of $1.05 billion; its shares were traded at around $11.09 with a P/E ratio of 13.1 and P/S ratio of 3.3. ALKS is...
|
|
|
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
Cost of goods manufactured and sold for the quarter ended December 31, 2009, was $10.1 million, of which $8.4 million related to RISPERDAL CONSTA, $1.1 million related to VIVITROL and $0.6 million related to the manufacture of polymer for exenatide once...
|
|
|
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Alkermes, Inc.(NASDAQ: ALKS) today reported financial results for its third quarter of fiscal 2010, which ended on December 31, 2009. Financial highlights: Quarterly revenues of $44.2 million, driven by record manufacturing...
|
|
|
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
WALTHAM, Mass.Alkermes, Inc.(NASDAQ: ALKS - News) today reported financial results for its third quarter of fiscal 2010, which ended on December 31, 2009. Financial highlights: Quarterly revenues of $44.2 million, driven by record manufacturing and royalty...
|
|
|
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
Record Sales of RISPERDAL CONSTA Company Expands Proprietary Pipeline to Include Long-Acting Versions of Two Blockbuster Medications WALTHAM, Mass.--(BUSINESS WIRE)--Alkermes, Inc.(NASDAQ: ALKS) today reported financial results for its third quarter of...
|
|
|
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
Alkermes, Inc.(NASDAQ: ALKS) today reported financial results for its Financial highlights: Quarterly revenues of $44.2 million, driven by record manufacturing and royalty revenues from RISPERDAL CONSTA. Worldwide sales of RISPERDAL CONSTA by Janssen,...
|
|
|
Alkermes reports 3Q loss, smaller than expected
CAMBRIDGE, Mass.(AP) -- Biotech drug developer Alkermes Inc. on Thursday reported a fiscal 2010 third-quarter loss on lower revenue, but the results topped Wall Street expectations.Alkermes said it lost $6.8 million, or 7 cents per share, in the quarter...
|
|
|
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
-- Record Sales of RISPERDAL(R) CONSTA(R)-- -- Company Expands Proprietary Pipeline to Include Long-Acting Versions of Two Blockbuster Medications -- WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc.(NASDAQ: ALKS) today reported financial results for its...
|
|
|
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
WALTHAM, Mass.- (BUSINESS WIRE) - Alkermes, Inc. (NASDAQ: ALKS) today reported financial results for its third quarter of fiscal 2010, which ended on December 31, 2009. Financial highlights: Other recent highlights: "The record RISPERDAL CONSTA sales in...
|
|
|
Alkermes Corporate Presentation to be Webcast at the BIO CEO & Investor Conference
Alkermes, Inc.(ALKS) announced today that its corporate presentation will be webcast live by the Biotechnology Industry Organization on Monday, February 8, 2010, at 3:00 p.m. ET from The Waldorf Astoria Hotel in New York City. The presentation may be...
|
|
|
Alkermes Corporate Presentation to be Webcast at the BIO CEO & Investor Conference
Companies mentioned in this article: Alkermes, Inc.WALTHAM, Mass. -- (BUSINESS WIRE) -- Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by the Biotechnology Industry Organization on Monday, February 8,...
|
|
|
Alkermes Corporate Presentation to be Webcast at the BIO CEO & Investor Conference
Companies mentioned in this article: Alkermes, Inc.WALTHAM, Mass. -- (BUSINESS WIRE) -- Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by the Biotechnology Industry Organization on Monday, February 8,...
|
